SARS-CoV-2 cell entry and targeted antiviral development

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zinuo, Du, Ruikun, Galvan Achi, Jazmin M., Rong, Lijun, Cui, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117542/
https://www.ncbi.nlm.nih.gov/pubmed/34002130
http://dx.doi.org/10.1016/j.apsb.2021.05.007
_version_ 1783691603229016064
author Chen, Zinuo
Du, Ruikun
Galvan Achi, Jazmin M.
Rong, Lijun
Cui, Qinghua
author_facet Chen, Zinuo
Du, Ruikun
Galvan Achi, Jazmin M.
Rong, Lijun
Cui, Qinghua
author_sort Chen, Zinuo
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era.
format Online
Article
Text
id pubmed-8117542
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81175422021-05-13 SARS-CoV-2 cell entry and targeted antiviral development Chen, Zinuo Du, Ruikun Galvan Achi, Jazmin M. Rong, Lijun Cui, Qinghua Acta Pharm Sin B Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era. Elsevier 2021-12 2021-05-13 /pmc/articles/PMC8117542/ /pubmed/34002130 http://dx.doi.org/10.1016/j.apsb.2021.05.007 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Chen, Zinuo
Du, Ruikun
Galvan Achi, Jazmin M.
Rong, Lijun
Cui, Qinghua
SARS-CoV-2 cell entry and targeted antiviral development
title SARS-CoV-2 cell entry and targeted antiviral development
title_full SARS-CoV-2 cell entry and targeted antiviral development
title_fullStr SARS-CoV-2 cell entry and targeted antiviral development
title_full_unstemmed SARS-CoV-2 cell entry and targeted antiviral development
title_short SARS-CoV-2 cell entry and targeted antiviral development
title_sort sars-cov-2 cell entry and targeted antiviral development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117542/
https://www.ncbi.nlm.nih.gov/pubmed/34002130
http://dx.doi.org/10.1016/j.apsb.2021.05.007
work_keys_str_mv AT chenzinuo sarscov2cellentryandtargetedantiviraldevelopment
AT duruikun sarscov2cellentryandtargetedantiviraldevelopment
AT galvanachijazminm sarscov2cellentryandtargetedantiviraldevelopment
AT ronglijun sarscov2cellentryandtargetedantiviraldevelopment
AT cuiqinghua sarscov2cellentryandtargetedantiviraldevelopment

Ejemplares similares